Abstract Mitotic regulatory pathways insure proper timing of mitotic entry, sister chromatid cohesion and separation, and cytokinesis. Disruption of this process results in inappropriate chromosome segregation and aneuploidy, and appears to contribute to cancer. Specifically, disregulation and somatic mutation of mitotic regulators has been observed in human cancers, and overexpression of mitotic regulators is common in aggressive and late stage tumors. However, the role of germline variation in mitotic pathways and risk of cancer is not well understood. We tested 1,084 haplotype-tagging and functional variants from 164 genes in mitotic regulatory pathways in 791 Caucasian women with breast cancer and 843 healthy controls for association with risk of overall and high grade breast cancer. Sixty-one single nucleotide polymorphisms (SNPs) from 40 genes were associated (P \ 0.05) with risk of breast cancer in a log-additive model. In addition, 60 SNPs were associated (P \ 0.05) with risk of high grade breast cancer. However, none of these associations were significant after Bonferroni correction for multiple testing. In gene-level analyses, CDC25C, SCC1/RAD21, TLK2, and SMC6L1 were associated (P \ 0.05) with overall breast cancer risk, CDC6, CDC27, SUMO3, RASSF1, KIF2, and CDC14A were associated with high grade breast cancer risk, and EIF3S10 and CDC25A were associated with both. Further investigation in breast and other cancers are needed to understand the influence of inherited variation in mitotic genes on tumor grade and cancer risk.
Introduction
Aneuploidy is a common event in breast cancer, occurring in approximately 80% of all breast tumors [1] , where it may play a role in tumor progression [2] . Whole chromosomal instability has also been detected as one of the earliest genetic alterations in premalignant lesions. One mechanism of chromosomal instability, and ultimately aneuploidy, is thought to be the abrogation of proper chromosome segregation during mitosis [3] . This process is regulated by checkpoints that insure the maintenance of sister chromatid cohesion during mitotic entry and progression, the timing of spindle assembly and attachment to centromeres, the fidelity of sister chromatid separation during the metaphase to anaphase transition, and the appropriate cleavage of daughter cells during cytokinesis [4] .
Multiple lines of evidence suggest a causal role for genetic mutations in these mitotic regulatory pathways in the development of chromosomal instability and cancer. Somatic mutations have been identified in genes involved in sister chromatid cohesion and in spindle assembly checkpoint genes in colon, breast, and gastric cancer cell lines [4] . Mice with hypomorphic mutations in spindle assembly checkpoint genes such as Mad2, Mad1, Bub1, BubR1, and Bub3 display elevated chromosome missegregation rates, and both Mad2 and BubR1 hypomorphic mice display increased rates of tumor development [3, 5] . In addition, overexpression of numerous mitotic regulators has been observed in many aggressive and late stage tumors, suggesting that disrupted mitosis contributes to tumor progression. Evidence that overexpression of Mad2 in transgenic mice promoted tumor formation confirmed this association [6] . Furthermore, recent studies have shown that delay or inhibition of cytokinesis by spindle poisons resulting in polyploidy cells can enhance tumor formation [7] .
While the presence of somatic mutations in mitotic genes is well established, the influence of germline variation on risk of cancer has been less extensively investigated. However, a number of associations have been identified including those between single nucleotide polymorphisms (SNPs) in LZTS1 and prostate cancer, MAD1L1 and MAD2L1 and lung cancer, STK15 and uterine cancer [8] [9] [10] , NEK10 and breast cancer [11] , and AURKA and several tumor types [12] . In addition, a promoter mutation in BIRC5 has been consistently associated with risk of colorectal cancer, lung cancer, and urothelial cancer [13, 14] .
We hypothesized that defects in the genes involved in mitosis including mitotic entry and progression, the spindle assembly checkpoint, and cytokinesis lead to an increased risk of breast cancer. We further postulated that variation in mitotic regulatory pathways is associated with high grade breast cancer risk given the relationship between histologic grade and mitotic index. To test these hypotheses, we investigated genes in these mitotic pathways using a haplotype-tagging approach to measure the association between mitotic genes and risk of overall and high grade breast cancer.
Materials and methods

Mayo Clinic study subjects
The details of the Mayo Clinic breast cancer case-control study have previously been published [15] 
Histologic grade
Histologic grade was determined using the Nottingham combined grading system. Tumors were classified as grade I (low), II (intermediate), and III (high), and only grade III (high) tumors were used in the high grade analyses.
Genotyping
A total of 1,741 samples (798 cases, 843 controls, and 100 duplicates) were genotyped on custom OPAs at Illumina Corporation (San Diego, CA, USA) using the Illumina GoldenGate assay. Only samples with call rates[95% were included in this analysis. Concordance between duplicate samples was 100%.
Statistical analysis
The genotype data were used to determine allele frequencies in cases and controls separately. Departure from Hardy-Weinberg equilibrium was assessed in controls using either a goodness of fit or exact test as appropriate. Single-SNP analyses were conducted using unconditional logistic regression adjusting for age and region of residence in all models. In the primary analysis, we tested each SNP in a log-additive (ordinal) model with one degree of freedom. To obtain additional information, we also used a two degree of freedom test, calculating odds ratios and 95% confidence intervals separately for heterozygotes and rare homozygotes. Significance of association for each gene was estimated using a likelihood ratio test, where the full model contained all principal components that captured [90% variance. Bonferroni correction was applied to adjust for multiple testing based on 164 genes and 1,084 SNPs.
Results
To address the hypothesis that inherited variation in mitotic signaling pathways influences risk of breast cancer, we tested 1,084 haplotype-tagging and functional variants from genes implicated in the regulation of mitotic entry (n = 50), mitotic integrity and the mitotic checkpoint (n = 62), and cytokinesis (n = 35) (Supplementary Table 1 ). Sixty-one SNPs from 40 genes were associated with risk of breast cancer in a log-additive model (P \ 0.05) ( Table 1, Supplementary Table 2 ). NEK1, EIF3S10, HEI10/CCNB1IP1, SMC6L1, FBXW7, RASGEF1A, CDC27, TLK2, CLIP170, AJUBA, PRC1, and CDC37L1 each contained multiple variants associated with breast cancer risk. To assess whether heterogeneity among histological tumor subtypes within the case population affected the results, we performed a subset analysis for estrogen receptor positive (ER-positive) breast cancers, which account for 83.9% of all cases. Results were very similar compared to those from the overall analysis, with 57 SNPs in 35 different genes significantly associated with risk of ER-positive breast cancer (P \ 0.05) (Supplementary Table 3 ). Thirty of these 35 genes (85.7%) contained SNPs that also had P \ 0.05 in the overall analysis. However, none of the SNPs associated with overall breast cancer or ER-positive breast cancer retained statistical significance after Bonferroni correction for 1,084 comparisons.
Histologic grading in breast cancer is comprised of the evaluation of three features: tubule formation, nuclear pleomorphism, and mitotic count. Tumor grade is associated with tumor aggressiveness and in part reflects the degree to which tumors retain normal mitotic control. High grade breast cancers are associated with poor prognosis compared to lower grade breast cancers, with mitotic index being the most important prognostic factor among the three features comprising histologic grade [16] . To determine whether genetic variation in mitotic genes is associated with high grade breast cancer, we performed a subset analysis comparing women with high grade breast cancers (n = 206) to normal controls (n = 843). Sixty SNPs from 34 genes were associated with an increased risk of high grade breast cancer (P \ 0.05) ( Table 2, Supplementary  Table 4 ). Twenty-one of these variants were also associated with overall breast cancer, and the directions of association were consistent in both analyses. In addition, the magnitude of effect was stronger for 19 of the SNPs in the high grade analysis compared to the overall analysis. However, as in the overall analysis, no SNPs were significant after Bonferroni correction for 1,084 comparisons. Three genes-CDC27, ROCK1, and SEPT6-contained six SNPs that were associated with high grade breast cancer risk but not overall breast cancer risk. An additional 17 genes represented by 24 SNPs were exclusively associated with high grade breast cancer risk. Fifteen of these genes [20] b Olson et al. [21] c Keleman et al. [15] d Wang et al. [22] Breast Cancer Res Treat (2011) 129:617-622 619
are involved in regulation of mitotic entry or the mitotic checkpoint. We next performed an exploratory analysis of breast cancer risk at the gene-level using principal components analysis to identify genes associated with breast cancer risk as well as genes not captured by single-SNP analyses alone (Table 3) . CDC25A, CDC25C, EIF3S10, SCC1/RAD21, TLK2, and SMC6L1 were associated (P \ 0.05) with overall risk of breast cancer. After Bonferroni correction for 164 gene tests, none of these associations retained statistical significance. Only two of the six genes associated with risk in the overall analysis, EIF3S10 and CDC25A, were also associated with risk of high grade breast cancer.
CDC6, CDC27, SUMO3, RASSF1, KIF2, and CDC14A were associated with high grade breast cancer only.
Discussion
Improper chromosome segregation during mitosis can lead to aneuploidy, which promotes tumor development and progression. To better understand the contribution of mitotic genes to cancer predisposition, we investigated whether inherited genetic variation in mitotic genes contributes to the development of breast cancer. Although the analysis of tagging SNPs from genes involved in mitotic Interestingly, only genes implicated in mitotic entry or the mitotic checkpoint were suggestive of gene-level associations. Four of the 50 mitotic entry genes (8.0%) and 8 of the 64 mitotic checkpoint genes (8.1%) tested in this study were associated with either overall or high grade breast cancer risk at the gene-level. In addition, several important genes encoding proteins involved in cohesinremoval, a process necessary for the proper separation of sister chromatids during the metaphase-anaphase transition, were represented by SNPs associated with risk of high grade breast cancer: SMC6, SCC1/RAD21, ESPL1, PTTG1, and CDC14A. In this process, separase (ESPL1) is released from securin (PTTG1) upon activation of the anaphasepromoting complex (APC), and the SCC1/RAD21 subunit of cohesin is cleaved by separase through a SMC5-SMC6-mediated mechanism [17] . Release of separase in this process also activates CDC14 in a positive-feedback loop, in which CDC14 dephosphorylates securin for continual ubiquitination by the APC [18] . Failure of this mechanism could result in non-disjunction and aneuploidy. Furthermore, while the functional association between the mitotic checkpoint and histologic grade has not been well studied, a study of invasive ductal breast carcinomas has shown that disregulation of components of the APC [19] is correlated with higher histologic grade in these tumors.
The strength of this study is that we performed a comprehensive evaluation of variation in mitotic genes and risk of breast cancer. While none of the reported associations retain statistical significance after adjusting for multiple testing, the results of these exploratory analyses warrant further investigation in larger, independent studies of breast cancer. Because of the large number of genes and SNPs assessed in this relatively small sample, we had limited statistical power to detect significant associations. Furthermore, the strong biological rationale used to select these genes suggests that the observed associations, while not statistically significant, may be genuine. In addition, we contribute to the relatively sparse literature on the relationship between genetic variation and breast cancer grade, which has important prognostic implications for women with breast cancer.
In summary, we report the first epidemiological study to comprehensively evaluate genetic variation in genes involved in mitotic regulatory pathways and breast cancer risk. We examined both individual SNP associations and gene-level associations and identified genes that are suggestive of association with risk of both overall and high grade disease. Since aneuploidy and chromosomal instability are commonly observed in human cancers, further investigation of the influence of inherited variation in mitotic genes on tumor grade and cancer risk in additional studies of both breast cancer and other cancer types is merited.
